Monoclonal Antibody Therapy in Parkinson's Disease - The End?
N Engl J Med
.
2022 Aug 4;387(5):466-467.
doi: 10.1056/NEJMe2207681.
Author
Alan Whone
1
Affiliation
1
From Translational Health Sciences, Bristol Medical School, University of Bristol, and the Movement Disorders Group, Bristol Brain Centre, Southmead Hospital, North Bristol NHS Trust - both in Bristol, United Kingdom.
PMID:
35921458
DOI:
10.1056/NEJMe2207681
No abstract available
Publication types
Editorial
Comment
MeSH terms
Antibodies, Monoclonal* / therapeutic use
Humans
Immunotherapy
Parkinson Disease* / drug therapy
Substances
Antibodies, Monoclonal